Truist Financial
LGND icon

Truist Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Truist Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$696K Buy
2,201
+256
+13% +$60.3K ﹤0.01% 1989
2026
Q1 		$388K Buy
1,945
+266
+16% +$52.6K ﹤0.01% 2230
2025
Q4 		$317K Hold
1,679
– – ﹤0.01% 2291
2025
Q3 		$297K Sell
1,679
-492
-23% -$73.1K ﹤0.01% 2320
2025
Q2 		$247K Sell
2,171
-277
-11% -$29.6K ﹤0.01% 2311
2025
Q1 		$257K Sell
2,448
-48
-2% -$5.43K ﹤0.01% 2234
2024
Q4 		$267K Sell
2,496
-149
-6% -$16.8K ﹤0.01% 2215
2024
Q3 		$265K Buy
+2,645
New +$266K ﹤0.01% 2208
2021
Q1 		– Sell
-2,608
Closed -$162K – 2694
2020
Q4 		$162K Sell
2,608
-4,283
-62% -$244K ﹤0.01% 2421
2020
Q3 		$410K Sell
6,891
-2,490
-27% -$170K ﹤0.01% 1826
2020
Q2 		$654K Buy
9,381
+3,224
+52% +$204K ﹤0.01% 1484
2020
Q1 		$279K Buy
6,157
+189
+3% +$10.7K ﹤0.01% 1908
2019
Q4 		$389K Buy
5,968
+2,150
+56% +$144K ﹤0.01% 2015
2019
Q3 		$237K Sell
3,818
-138
-3% -$8.66K ﹤0.01% 720
2019
Q2 		$282K Sell
3,956
-271
-6% -$20K ﹤0.01% 695
2019
Q1 		$332K Buy
4,227
+806
+24% +$61.1K 0.01% 653
2018
Q4 		$289K Sell
3,421
-274
-7% -$29.2K 0.01% 653
2018
Q3 		$632K Sell
3,695
-133
-3% -$20.1K 0.01% 548
2018
Q2 		$494K Sell
3,828
-338
-8% -$37.7K 0.01% 578
2018
Q1 		$429K Sell
4,166
-37
-0.9% -$3.66K 0.01% 598
2017
Q4 		$359K Sell
4,203
-93
-2% -$8.06K 0.01% 647
2017
Q3 		$365K Sell
4,296
-26
-0.6% -$2.06K 0.01% 640
2017
Q2 		$327K Sell
4,322
-133
-3% -$9.3K 0.01% 654
2017
Q1 		$294K Sell
4,455
-447
-9% -$29.4K 0.01% 698
2016
Q4 		$311K Sell
4,902
-394
-7% -$24.9K 0.01% 689
2016
Q3 		$337K Buy
5,296
+1,248
+31% +$91.6K 0.01% 665
2016
Q2 		$301K Buy
+4,048
New +$300K 0.01% 686

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Truist Financial's LGND Position: Q2 2026 in Review

Truist Financial increased its Ligand Pharmaceuticals (LGND) stake by 13% in Q2 2026, buying an estimated $60.3K and bringing the position to 2,201 shares worth $696K. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

Truist Financial first reported a position in LGND in Q2 2016 and has held it in 27 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Truist Financial held 2,201 shares of Ligand Pharmaceuticals worth $696K as of Q2 2026.
  • Truist Financial bought 256 Ligand Pharmaceuticals shares in Q2 2026, an estimated $60.3K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1989 holding.
  • Truist Financial first reported a position in Ligand Pharmaceuticals in Q2 2016 and has held it in 27 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.